LT5524B - Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas - Google Patents

Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas Download PDF

Info

Publication number
LT5524B
LT5524B LT2008003A LT2008003A LT5524B LT 5524 B LT5524 B LT 5524B LT 2008003 A LT2008003 A LT 2008003A LT 2008003 A LT2008003 A LT 2008003A LT 5524 B LT5524 B LT 5524B
Authority
LT
Lithuania
Prior art keywords
meldonium
pharmaceutical composition
lamivudine
reverse transcriptase
stavudine
Prior art date
Application number
LT2008003A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2008003A (en
Inventor
Vija Klusha
Sergejs Isajevs
Jolanta Pupure
Juris Rumaks
Valentina Gordjushina
Immanuels Taivans
Ivars Kalvinsh
Original Assignee
Latvian Institute Of Organic Synthesis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37442067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT5524(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Latvian Institute Of Organic Synthesis filed Critical Latvian Institute Of Organic Synthesis
Publication of LT2008003A publication Critical patent/LT2008003A/xx
Publication of LT5524B publication Critical patent/LT5524B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LT2008003A 2005-08-15 2008-01-18 Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas LT5524B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-05-95A LV13544B (en) 2005-08-15 2005-08-15 Pharmaceutical composition containing reverse transcriptase inhibitor and meldonium

Publications (2)

Publication Number Publication Date
LT2008003A LT2008003A (en) 2008-07-25
LT5524B true LT5524B (lt) 2008-10-27

Family

ID=37442067

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2008003A LT5524B (lt) 2005-08-15 2008-01-18 Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas

Country Status (17)

Country Link
US (1) US7700576B2 (lv)
EP (1) EP1933823B1 (lv)
JP (1) JP5027809B2 (lv)
CN (1) CN101252925B (lv)
AR (1) AR066995A1 (lv)
AT (1) ATE493123T1 (lv)
DE (1) DE602006019293D1 (lv)
EE (1) EE05529B1 (lv)
ES (1) ES2361185T3 (lv)
HN (1) HN2006029085A (lv)
LT (1) LT5524B (lv)
LV (1) LV13544B (lv)
PE (1) PE20070233A1 (lv)
SV (1) SV2007002655A (lv)
UA (1) UA90162C2 (lv)
UY (1) UY29751A1 (lv)
WO (1) WO2007021164A1 (lv)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA021588B1 (ru) * 2009-06-25 2015-07-30 Тетра Сиа Бетаиновые соли ацетилсалициловой кислоты
LV14848B (lv) * 2012-10-25 2015-06-20 Latvijas Organiskās Sintēzes Institūts Farmaceitiska kompoz&imacr;cija trimetilam&imacr;na-N-oks&imacr;da l&imacr;me&ncedil;a pazemin&amacr;&scaron;anai

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481218A (en) 1978-11-27 1984-11-06 Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr 3-(2,2,2-Trimethylhydrazinium)propionate and method for the preparation and use thereof
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
WO1991017159A1 (en) 1990-05-02 1991-11-14 Iaf Biochem International Inc. 1,3-oxathiolane nucleoside analogues
US5130421A (en) 1988-03-24 1992-07-14 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
EP0560275A1 (en) 1992-03-11 1993-09-15 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of L-carnitine for treating carnitine-depleted HIV-seropositive patients

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481218A (en) 1978-11-27 1984-11-06 Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr 3-(2,2,2-Trimethylhydrazinium)propionate and method for the preparation and use thereof
US4724232A (en) 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5130421A (en) 1988-03-24 1992-07-14 Bristol-Myers Company Production of 2',3'-dideoxy-2',3'-didehydronucleosides
WO1991017159A1 (en) 1990-05-02 1991-11-14 Iaf Biochem International Inc. 1,3-oxathiolane nucleoside analogues
EP0560275A1 (en) 1992-03-11 1993-09-15 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of L-carnitine for treating carnitine-depleted HIV-seropositive patients

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BROCKLEHURST P, VOLMINK J.: "Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.", COCHRANE DATABASE SYST REV., 2002, pages 003510
LEWIS W. ET AL.: "Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria", J. CLIN. INVEST., 1992, pages 1354 - 1360, XP002963913, DOI: doi:10.1172/JCI115722

Also Published As

Publication number Publication date
CN101252925A (zh) 2008-08-27
LT2008003A (en) 2008-07-25
JP2009504731A (ja) 2009-02-05
LV13544B (en) 2007-05-20
UY29751A1 (es) 2007-03-30
UA90162C2 (ru) 2010-04-12
DE602006019293D1 (de) 2011-02-10
WO2007021164A1 (en) 2007-02-22
US7700576B2 (en) 2010-04-20
AR066995A1 (es) 2009-09-30
ES2361185T3 (es) 2011-06-14
HN2006029085A (es) 2007-11-16
EE05529B1 (et) 2012-04-16
EP1933823B1 (en) 2010-12-29
JP5027809B2 (ja) 2012-09-19
EP1933823A1 (en) 2008-06-25
ATE493123T1 (de) 2011-01-15
EE200800014A (et) 2008-06-16
SV2007002655A (es) 2007-04-12
US20090137522A1 (en) 2009-05-28
CN101252925B (zh) 2012-04-25
PE20070233A1 (es) 2007-06-08

Similar Documents

Publication Publication Date Title
CN104185420B (zh) 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
US20020169140A1 (en) Combination therapy for reduction of toxicity of chemotherapeutic agents
US5719132A (en) Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
CA2633603C (en) Pharmaceutical combination
JP2004517864A (ja) ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
EP1272897B1 (en) Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis, cirrhosis and fatty liver
Nelson et al. Emtricitabine (FTC) for the treatment of HIV infection
US20170232032A1 (en) Pharmaceutical compositions for treating ebola virus disease
AU2001238124A1 (en) Adenosine a2a receptor antagonists for treating and preventing hepatic fibrosis,cirrhosis and fatty liver
Margot et al. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1
LT5524B (lt) Farmacinė kompozicija, kurios pagrindą sudaro atvirkštinės transkriptazės inhibitorius ir meldoniumas
WO2021205437A1 (en) Pharmaceutical compositions for treating corona virus disease
AU755633B2 (en) Antiviral combinations
EP0839033B1 (en) Use of l-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral
Lemberg et al. Tolerabilities of antiretrovirals in paediatric HIV infection
MXPA03005382A (es) Terapia combinada de dapd con un inhibidor de inosino monofosfato dehidrogenasa.
US20140065246A1 (en) Intracellular calcium modulation for cancer treatment
US7745455B2 (en) Zalcitabine (ddC) boosted lamivudine (3TC) compositions for antiretroviral therapy
US20170246241A1 (en) Methods for the Selective Treatment of Tumors by Calcium-Mediated Induction of Apoptosis
Blonk Clinical pharmacology of the HIV integrase inhibitor raltegravir: drug-drug interactions and pharmacokinetics
KR20230044481A (ko) 감기약 및 항바이러스제
CA2284483A1 (en) Mixtures of at least two reverse transcriptase inhibitors and hydroxycarbamide, in particular for inhibiting retroviral spread

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20140808